You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
CA 125 |
||
Geisinger Epic Procedure Code: LAB1910
Geisinger Epic ID: 19447
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum (preferred) or plasma | |
Preferred collection container: |
||
Alternate Collection Container: |
3 mL green/yellow-top (plasma separator) tube
|
|
Specimen required: |
1 mL serum or plasma; minimum 0.5 mL. | |
Special notes: |
Preferred specimen collection device is a 3.5 ml serum-separator tube. A 3 mL plasma separator tube is also acceptable. | |
Patient preparation: |
Sample should not be drawn for two months after abdominal surgery and at least three weeks after the completion of primary chemotherapy. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge to separate serum or plasma within 2 hours of collection. | |
Transport temperature: |
Refrigerated (preferred). Frozen specimen also acceptable. | |
Specimen stability: |
Stable 5 days at 2-8° C, 6 months frozen. | |
Rejection criteria: |
Stability limits exceeded. | |
TEST DETAILS |
||
Reference interval: |
<= 38.1 U/mL | |
Additional information: |
HAMA Warning: Patient specimens containing a human antimouse antibody may interfere with results. | |
CPT code(s): |
86304 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Cancer antigen 125. | |
Methodology: |
Roche Electrochemiluminescence Immunoassay. Patient results determined by assays using different manufacturers or methods may not be comparable. |
|
Synonyms: |
CA125, Cancer antigen 125
|
|
Clinical significance: |
The CA125 level can provide prognostic information in the follow-up management of patients with ovarian carcinoma. CA125 is not recommended as a cancer screening procedure to detect cancer in the general population. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM Sheng-Ying (Margaret) Lo, PhD, DABCC |
|
| Review Date: | 02/13/2024 | |